Background
==========

Many epidemiologic and experimental studies support an association between higher serum levels of sex steroid hormones and an increased risk of postmenopausal breast cancer, especially for estrogen receptor (ER)-positive breast cancers \[[@B1]-[@B6]\]. However, the prognostic role of the serum level of these hormones in newly diagnosed breast cancer patients is still unclear. Although several studies have reported that higher serum testosterone levels at diagnosis were associated with poor prognosis in postmenopausal women with breast cancer, other studies demonstrated no such association \[[@B7]-[@B9]\]. The role of testosterone in breast cancer has been attributed to its conversion to estrogen by aromatase.

Estrogen has been found to contribute significantly to breast tumor formation and growth \[[@B10]-[@B13]\]. High serum estradiol levels were reported to be associated with specific gene expression patterns in breast cancer tissue. \[[@B14]\]. In estrogen-dependent tumors, estrogen promotes cell proliferation and, suppresses apoptosis, by directly modulating gene transcription, making estrogen an important target in treatment \[[@B15]\].

ER status is important in breast cancer carcinogenesis and progression. Circulating estrogen binds to ER in breast cancer cells and stimulates cell division and growth. However, recent studies provided further molecular insights into the estradiol-dependent breast carcinogenesis, finding that estradiol may act independently of ER \[[@B16]-[@B18]\].

Serum estradiol level is significantly lower in postmenopausal than in premenopausal women. And postmenopausal women have been consistent in E2 levels without variation according to menstrual cycle. Here, we report the results of a single-institutional retrospective analysis of the prognostic importance of preoperative serum estradiol level in postmenopausal breast cancer patients. Our hypothesis is that serum estradiol level may be significant prognostic factor in postmenopausal breast cancer.

Methods
=======

The Seoul national university hospital breast care center database was reviewed for the medical records of postmenopausal women who underwent curative surgery between September 2006 and December 2008 for newly diagnosed invasive breast cancer and for whom we had the information on serum estradiol levels within 3 months prior to surgery. Patients who received neoadjuvant chemotherapy, synchronous bilateral breast cancer or those with metastasis at diagnosis time were excluded from the study. Women were defined as postmenopausal if they had a bilateral oophorectomy, were aged 60 years or older, or were aged under 60 years with amenorrhea for at least 12 months, and their serum follicular stimulating hormone (FSH) levels satisfied the diagnostic criteria for menopause (FSH\>30 mIU/mL). We identified 313 postmenopausal women eligible for the study (Figure [1](#F1){ref-type="fig"}).
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Serum levels of E2 were measured by radioimmunoassay (RIA) using commercial kits (Biosource, Nivelles, Belgium), with intra- and inter-assay coefficients of variation (CV) of 4.9% and 5.2%, respectively. FSH were measured by immunoradiometric assay (IRMA) using commercial kits (Biosource), with a detection limit of 0.1 mlU/mL, and intra- and inter assay CVs of 3.3% and 7.1%, respectively.

Pathology data, including tumor size, grade, lymph node involvement, and immunohistochemistry results on hormone receptors expression, were reviewed. A cut-off value of 1% or more positively stained nuclei in the high-power fields was used to define ER and PR positivity. Patients were recommended to undergo adjuvant therapy and surveillance according to the St Gallen and/or NCCN guidelines.

Distant metastasis excluded local breast recurrence, axillary lymph node recurrence and newly diagnosed contralateral breast cancer. The time of metastasis was defined as the date confirmed by biopsy or image finding. Metastasis-free survival defined as the time period from the date of breast surgery to that of first diagnosis with distant metastasis by biopsy results or image or last follow-up. The Cox regression model was utilized to identify significant independent factors related to distant metastasis.

Student's t-tests were used to compare E2 levels in two groups, and Pearson\'s correlation test was used to test the relationships between E2 level and age and body mass index (BMI). The Kaplan-Meier method and log-rank test were used for survival analysis. The Cox regression model was utilized to identify significant independent factors related to distant metastasis. The variables included in the final model were defined by backward selection. We excluded the missing or unknown data when we performed statistical analysis. Significance was defined as *p*\<0.05. All statistical analyses were performed using SPSS (version 19.0 SPSS Inc., Chicago, IL, USA). Written informed consent was taken prior to surgery in all patients and the study protocol including the use of the database was approved by the Institutional Review Board of Seoul National University Hospital and met the guidelines of the responsible governmental agencies.

Results
=======

The clinical and histopathological characteristics of the studied patients are listed in Table [1](#T1){ref-type="table"}. Patients ranged in age from 45 to 83 years, with 3 patients having undergone bilateral oophorectomy before diagnosis of breast cancer. Of the 195 patients with ER or PR positive tumors, 192 received adjuvant hormonal therapy.

###### 

The clinical and histopathological characteristics of the included patients

  **Characteristics**         **Number of patients (% of total)**                             
  --------------------------- ------------------------------------- ------------ ------------ ---------
  Enrolled patients           313                                   190          123           
  Tumor size (mean), cm       2.17                                  2.03         2.40          
    \<2                       170                                   121(63.7%)   49(39.8%)    \<0.001
    2-5                       138                                   65(34.2%)    73(59.3%)     
    ≥5                        5                                     4(2.1%)      1(0.8%)      
  Nodal status                                                                                 
    0                         206                                   130(68.4%)   76(61.8%)    0.310
    1-3                       81                                    44(23.2%)    37(30.1%)    
    4-9                       14                                    7(3.7%)      7(5.7%)      
    ≥10                       12                                    9(4.7%)      3(2.4%)      
  Nuclear grade                                                                               \<0.001
    Grade 1 or 2              127                                   109(57.4%)   18(14.6%)    
    Grade 3                   175                                   76(40.0%)    99(80.5%)    
    Unknown                   11                                    5(2.6%)      6(4.9%)      
  Histologic grade                                                                            \<0.001
    Grade 1 or 2              131                                   113(59.5%)   18(14.6%)    
    Grade 3                   153                                   59(31.0%)    94(76.4%)    
    Unknown                   29                                    18(9.5%)     11(9.0%)     
  PR status                                                                                   \<0.001
    Positive                  133                                   128(67.4%)   5(4.1%)      
    Negative                  180                                   62(32.6%)    118(95.9%)   
  HER2/neu status                                                                             \<0.001
    Positive                  45                                    9(4.7%)      36(29.3%)    
    Negative                  246                                   170(89.5%)   76(61.8%)    
    Unknown                   22                                    11(5.8%)     11(8.9%)     
  Operation                                                                                   0.014
    Conservation              175                                   117(61.6%)   58(47.2%)    
    Mastectomy                138                                   73(38.4%)    65(52.8%)    
  Adjuvant chemotherapy                                                                       \<0.001
    No                        131                                   103(54.2%)   28(22.8%)    
    Yes                       182                                   87(45.8%)    95(77.2%)    
  Adjuvant Radiotherapy                                                                       0.129
    No                        133                                   74(38.9%)    59(48.0%)    
    Yes                       180                                   116(61.1%)   64(52.0%)    
  Adjuvant hormonal therapy                                                                    
    No                                                              3(1.6%)                   
    SERM                                                            36(18.9%)                 
    AI                                                              137(72.1%)                
    Switch\*                                                        14(7.4%)                  
  Distant metastasis                                                7(3.7%)      15(12.2%)    0.006

*Abbreviations*: *ER* estrogen receptor, *PR* Progesterone receptor, *SERM* selective estrogen modulator, *AI* aromatase inhibitor.

Switch\*: Tamoxifen for 2--3 year, and then aromatase inhibitor to complete 5 year.

The overall median level of estradiol was 13.0 pg/ml, with mean estradiol levels higher in patients with ER positive than ER negative tumors (14.36±7.85 pg/ml *vs*. 12.97 ± 7.37 pg/ml, p=0.69) (Table [2](#T2){ref-type="table"}). Serum levels of estradiol did not correlate with age (Pearson correlation coefficient=0.033, *p*=0.56) or BMI (Pearson correlation coefficient =0.106, *p*=0.06).

###### 

Mean estradiol levels according to subgroups

                                    **Estradiol level (Mean±SD, pg/mL)**   **p value**
  ------------------ -------------- -------------------------------------- -------------
  Tumor size         \<2 cm         13.69±7.17                             0.75
                     ≥2 cm          13.97±8.28                              
  Nodal status       N0             13.93±7.99                             0.71
                     N1-3           13.59±7.09                              
  ER                 Negative       12.97±7.37                             0.69
                     Positive       14.36±7.85                              
  PR                 Negative       13.41±7.52                             0.27
                     Positive       14.37±7.89                              
  Her-2              Negative       14.09±7.80                             0.81
                     Positive       14.40±7.33                              
  Histologic grade   Grade 1 or 2   13.91±8.05                             0.80
                     Grade 3        13.68±7.25                              
  Nuclear grade      Grade 1 or 2   13.78±8.38                             0.89
                     Grade 3        13.90±7.11                              

*Abbreviations*: *SD* Standard deviation, *ER* estrogen receptor, *PR* Progesterone receptor.

During a median follow-up time of 52.0 months after diagnosis (range, 11 to 77 months), 3 patients had locoregioanl recurrence, 2 patients had contralateral breast cancer, and 21 patients had distant metastasis as the first event. And one patient with local recurrence eventually had distant metastasis. As the results, 22 patients were diagnosed with distant metastases, 7 in the ER positive and 15 in the ER negative group. Mean serum estradiol level was significantly higher in patients with than without metastasis (17.41±8.34 pg/ml *vs*. 13.54±7.58 pg/ml, *p*=0.02).

We performed Kaplan-Meier survival analysis to evaluate the prognostic effect of estradiol according to ER status. Using the cut-off values 13 pg/ml, which is the median value in this study, we found that metastasis free survival was lower in ER-positive patients with higher than with lower estradiol level, although the difference was not statistically significant (Figure [2](#F2){ref-type="fig"}a). In ER negative patients, higher estradiol levels were significantly associated with increased risk of metastasis (Log-rank=0.02) (Figure [2](#F2){ref-type="fig"}b).

![**Metastasis-free survivals according to ER status. a**. Metastasis-free survival was lower in ER-positive patients with higher than with lower estradiol level, although the difference was not statistically significant (Log-rank=0.25). **b**. In ER negative patients, higher estradiol levels were significantly associated with increased risk of metastasis (Log-rank=0.02).](1471-2407-13-503-2){#F2}

To confirm the prognostic effect of serum estradiol in ER negative breast cancer patients, we performed a multivariate analysis using a Cox hazard model. The estradiol level was found to be an independent negative prognostic indicator of metastasis free survival (HR, 3.32; 95% CI, 1.05 to 10.51; p=0.04) (Table [3](#T3){ref-type="table"}).

###### 

Univariate and multivariate analyses of prognostic factors including serum E2 level for metastasis-free survival according to ER status

                         **ER positive group**   **ER negative group**                                                                                          
  ---------------------- ----------------------- ----------------------- ------- ------ ------------- ------ ------- ------------ --------- ------ ------------ ------
  Age                    1.06                    0.97-1.16               0.24                                1.02    0.95-1.09    0.63                           
  BMI, ≥23 kg/m^2^       1.22                    0.52-2.86               0.64                                1.02    0.37-2.82    0.97                           
  HER2/neu positive      0.99                    0.98-1.01               0.69                                0.97    0.33-2.84    0.96                           
  Tumor size, \>2 cm     10.65                   1.28-88.48              0.03    3.75   0.41-33.98    0.24   4.75    1.07-21.06   0.04      1.85   0.37-9.27    0.45
  Node metastasis                                                                                                                                                
  0                      Ref.                                                    Ref.                        Ref.                                                
  1-3                    1.47                    0.13-16.25              0.75    1.12   0.10-12.66    0.93   4.00    1.17-13.70   0.03      2.45   0.65-9.31    0.19
  \>3                    18.96                   3.47-103.63             0.001   9.05   1.50-54.45    0.02   10.70   2.67-42.90   0.001     2.99   0.62-14.36   0.17
  Nuclear grade 3        3.06                    1.06-8.83               0.04    1.21   0.08-19.62    0.87   1.11    0.53-2.34    0.78                           
  Histologic grade 3     3.59                    1.24-10.38              0.02    8.04   0.54-120.81   0.13   1.16    0.55-2.45    0.69                           
  ELTE                   2.91                    0.65-13.00              0.16                                8.28    2.63-26.06   \<0.001   4.24   1.18-15.18   0.03
  E2 level, \>13 pg/ml   2.54                    0.49-13.13              0.27                                3.373   1.07-10.61   0.04      3.32   1.05-10.51   0.04
  Chemotherapy           2.49                    0.92-6.75               0.07                                                                                    

A multivariate analysis was set by using all of the predictors with p values under 0.05 in univariate analysis.

*Abbreviations*: *ER* estrogen receptor, *BMI* Body mass index, *ELTE* endolymphatic tumor emboli, *E2* Estradiol.

We also found that, ER negative patients with higher estradiol levels were significantly associated with increased risk of diasease-sepecific events (including locoregional recurrence and contralateral recurrence). (Log rank=0.034) In multivariate analysis using a Cox hazard model, high E2 (\>13 pg/ml) of ER negative tumors was negative prognostic factor for disease-free survival (HR, 2.717), but the p value was 0.058.

Discussion
==========

We have shown here that higher serum estrogen levels contribute to the risk of distant metastasis in postmenopausal breast cancer patients with ER negative tumors. Rock et al. \[[@B7]\] have also shown the significant association between serum estradiol level and patient's survival in a nested case--control cohort of a randomized trial of diet intervention (Women's Health Eating and Living study), although that study did not include subgroup analysis based on ER expression status.

Our observation, that serum estradiol level affects prognosis only in patients with ER negative tumors, was interesting since estradiol is thought to play a key role in the carcinogenesis of ER positive tumors. Indeed, our findings are supported by recent experimental studies showing that estradiol regulates the progression of ER negative breast cancer cell lines. For example, Gupta et al. \[[@B16]\] reported that estrogen promotes the growth, stromalization, and angiogenesis of an ER negative breast cancer cell line by systemic induction of host angiogenesis and bone marrow-derived stromal cell recruitment. Similarly, Banka et al. \[[@B17]\] showed that estradiol treatment of ovariectomized mice injected with an ER negative mouse mammary carcinoma cell line markedly increased the incidence of lung metastasis. These studies suggest that estradiol can act as a potent metastasis-promoter in ER negative tumors by a novel mechanism involving the host microenvironment. And another plausible explanation might be possibility that more aggressive ER negative breast tumors are associated with higher estrogen levels because they share a common cause, for example, such tumors could elicit a strong inflammatory response which both enables metastasis and also upregulates aromatase activity in surrounding tissues.

Indirect evidence supporting the role of estradiol in ER negative tumor development can also be found in human clinical studies. Ovariectomy was shown to signicantly reduce the incidence of both ER negative and ER positive tumors \[[@B19],[@B20]\]. Prophylactic oophorectomy can prevent the development of breast cancers in BRCA1 mutation carriers in whom the main types of breast cancer are ER negative \[[@B21]-[@B23]\]. However, it is unclear whether it may be the consequence of inhibition of the transition of luminal of ER positive cells to negative or inhibition of tumorigenesis itself. And among BRCA1 mutation carriers older than age 50, no risk reduction was evident with prophylactic oophorectomy \[[@B23]\]. It is also unclear whether the estrogen lowering treatments like aromatase inhibitors were effective in ER negative tumors. According to the study of Jones et al. \[[@B24]\] which was central review of pathological specimens from patients entered in BIG 1--98 trials, aromatase inhibitors might have advantage in only patients whose tumor express ER. However, they didn't measure the preoperative estradiol level, so it was impossible to compare the difference of effect according to estradiol level in patients with ER negative or positive tumors.

It is unclear why serum estradiol level was not significantly associated with the development of metastasis in ER positive breast cancer patients. One possible explanation is that almost all patients with ER positive tumors in our study cohort (98.4%) received anti-estrogen treatment with either tamoxifen or aromatase inhibitors. In addition, there were fewer events in ER positive tumors, so it might act as cause of limited power.

Premenopausal women experience changes in their serum estrogen levels throughout their menstrual cycles. In contrast, postmenopausal women have been more consistent in E2 levels, because of the absence of the variability of hormone levels with the menstrual cycle. Therefore, to analysis the difference of prognosis according to serum E2 level in premenopausal women, constant measure of E2 in time is important.

This study has several limitations. Due to its retrospective nature, there may have been a selection bias. Specially, the measurement of estradiol levels was not performed as a part of the prospective design. Some were measured for other studies, and others measured for standard element of the work-up for breast cancer by special physicians during different periods. Also, the median follow-up period of 52 months was not sufficient to assess the prognostic effect in breast cancer patients, especially in patients with ER positive tumors. And our findings are based on a quite small number of cases. Further confirmatory studies are needed.

Conclusions
===========

We found that a higher level of serum estradiol had a negative prognostic effect in postmenopausal women with ER negative breast cancer. These findings are hypothesis generating, suggesting that an estrogen-rich microenvironment can facilitate the progression of ER negative tumors. Additional in vivo and prospective cohort studies are needed to address this hypothesis.
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